The metabolic and appetite tools discussed in this article are interesting precisely because they push against these specific failure points: the rising maintenance target, the loosening habits, and the storage drift that accompanies prolonged overfeeding
Watch the Investor Day Presentation To view or add a comment, sign in Beyond its well-documented role in recovery, BPC-157 is increasingly appearing in functional wellness protocols alongside GLP-1 therapy with practitioners reporting patient benefits in energy, inflammation, and gut health that support broader metabolic goals
T, thoracic spine
The advent of dual agonists such as tirzepatide underscores a new era in obesity treatment, demonstrating superior efficacy with potentially fewer side effects
In pooled analyses of the STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and STEP-HFpEF-DM trials, GLP-1 RA had consistent beneficial effects on HF-related symptoms, exercise function, and inflammatory markers in patients receiving diuretics with obesity-related HFpEF [82]
